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Abstract
Background: According to current clinical guidelines mutational analysis for KRAS and NRAS is recommended prior
to EGFR-directed therapy of colorectal cancer (CRC) in the metastatic setting. Therefore, reliable, fast, sensitive and
cost-effective methods for routine tissue based molecular diagnostics are required that allow the assessment of the
CRC mutational status in a high throughput fashion.
Methods: We have developed a custom designed assay for routine mass-spectrometric (MS) (MassARRAY®, Agena
Bioscience) analysis to test the presence/absence of 18 KRAS, 14 NRAS and 4 BRAF mutations. We have applied this assay
to 93 samples from patients with CRC and have compared the results with Sanger sequencing and a chip hybridization
assay (KRAS LCD-array Kit, Chipron). In cases with discordant results, next-generation sequencing (NGS) was performed.
Results: MS detected a KRAS mutation in 46/93 (49 %), a NRAS mutation in 2/93 (2 %) and a BRAF mutation in 1/93 (1 %)
of the cases. MS results were in agreement with results obtained by combination of the two other methods in 92 (99 %)
of 93 cases.
In 1/93 (1 %) of the cases a G12V mutation has been detected by Sanger sequencing and MS, but not by the chip assay.
In this case, NGS has confirmed the G12V mutation in KRAS.
Conclusions: Mutational analysis by MS is a reliable method for routine diagnostic use, which can be easily extended for
testing of additional mutations.
Background
Colorectal carcinoma (CRC) is the third most common
cancer in men and the second most common cancer in
woman worldwide with approximately 694.000 deaths
reported in 2012 [1]. It has long been recognized that
the epidermal growth factor receptor (EGFR) pathway
is frequently activated in CRC [2]. This results in pro-
motion of tumor growth, inhibition of apoptosis, vascular
proliferation, invasion, and metastasis.
Therefore, targeted therapies against EGFR such as
cetuximab and panitumumab have been developed and
are currently approved for the treatment of metastatic
disease (mCRC), irrespective of whether applied in
combination with conventional chemotherapy or as
single agents.
Downstream signalling of EGFR activates RAS- and
RAF-genes that are members of this pathway and can
harbour oncogenic mutations in 30–60 % (KRAS) [3–6],
5–20 % (BRAF) [7–9] and 1–3 % (NRAS) [10, 11] of
cases respectively.
It has been shown that activating mutations of KRAS
or NRAS lead to a consecutive activation of the RAS-
RAF pathway downstream of EGFR and consequently
result in resistance to anti-EGFR therapy [12–14]. For
this reason, currently the American Society of Clinical
Oncology (ASCO) [15] and the European Society for
Medical Oncology (ESMO) [16] recommend treatment
with anti-EGFR antibodies only in mCRC patients with
RAS wild-type tumors. This approach is reasonable since
patients with mutated RAS have no benefit from this
therapy. Additionally, it reduces overall treatment costs
and prevents patients from unnecessary side effects. In
2009, when the recommendations were published, the
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definition of a RAS wild type tumor was based on a
negative result, when the most common mutations in
codon 12 and 13 (97 %) of exon 2 were analyzed. How-
ever, since recent studies suggest that resistance to anti-
EGFR therapy might also be mediated by less frequent
mutations of KRAS [10, 17–19] or NRAS [10, 11, 18] in
codon 61 of exon 3 as well as codon 117 and 146 of
exon 4 (3 %), it is now mandatory to include those mu-
tational hotspots in the genetic testing, as well. This fact
is underlined by a recent study where approximately
20 % of tumors originally classified as having no KRAS
mutations in exon 2, harboured another mutation in one
of the RAS genes [11].
As with KRAS mutations (especially codon 12), BRAF
mutations have also been linked to a worse patient prog-
nosis in CRC [8, 20]. However, it is important to note
that the prognostic impact of the presence of a BRAF
mutation is dependent on the microsatellite status:
whereas microsatellite-stable BRAF mutated CRC are
associated with a worse, microsatellite-instable BRAF
mutated tumors are associated with a better prognosis
than BRAF wild type CRC [21]. However, the presence
of BRAF mutations currently is believed not to be pre-
dictive for the response to anti-EGFR therapies [22].
Furthermore, recent studies showed that acetylsalicylic
acid and other nonsteroidal anti-inflammatory drugs are
associated with reduced disease recurrence and im-
proved outcome in CRC and that these benefits are lim-
ited to patients with PIK3CA-mutated cancers [17, 19,
23]. Also other genetic mutations that are frequently al-
tered in CRC such as p53 [24] or PTEN [25] may serve
as prognostic or predictive biomarkers. While very
promising, all lack clinical significance at present.
When the first anti-EGFR therapies for mCRC entered
the arena, institutes of pathology expanded their expert-
ise in molecular techniques in order to be able to evalu-
ate the mutational status of KRAS, NRAS and BRAF.
Accurate mutation assessment depends on several fac-
tors such as available tissue, DNA-quality, percentage of
tumor cells as well as the specificity and sensitivity of
various test systems [26].
When choosing an assay for routine diagnostics, add-
itional factors such as workload, time-to-results, hands-on
time, equipment, assay costs, assay flexibility and robust-
ness of the technique applied needed to be addressed [27].
Methods currently available for KRAS, NRAS and BRAF
mutational analysis include Sanger sequencing, which is
still regarded as the gold standard, and numerous alterna-
tives as allele-specific PCR [28], single nucleotide primer
extension assays [27, 29], pyrosequencing [30], real-
time PCR [31], high resolution melting curve analysis
[30, 32], amplification refractory mutation system
(ARMS)-Scorpion assay [33], strip or chip assay com-
bining PCR followed by hybridization to a KRAS or
NRAS-specific probe [27, 34], next-generation sequen-
cing (NGS) [34] and matrix assisted laser desorption/
ionization mass spectrometry (MALDI MS) [17]. How-
ever, past studies with MALDI MS mainly applied gen-
etic panels provided by the manufacturer that cover
many mutations that are not recommended to assess.
In consequence these panels are not cost-effective for
routine use.
Therefore, we developed a MALDI MS test assay for the
simultaneous detection of KRAS, NRAS and BRAF muta-
tions in a routine high throughput setting and imple-
mented an optimised workflow. We compared the data
generated by this assay to data from standard RAS muta-
tion detection methods, specifically the KRAS 1.4 LCD
Array Kit (Chipron, Berlin) and Sanger Sequencing. Cases
with discordant mutation results were subjected to NGS
analysis to definitely clarify the mutational status.
Methods
Patients
93 tumor samples of patients with CRC were analysed
using a custom panel of mutation assays across the KRAS,
NRAS and BRAF oncogenes with the Agena Bioscience
MALDI MS platform.
Sample preparation and DNA extraction
Hematoxylin and Eosin (H&E)-stained slides from
formalin-fixed paraffin-embedded (FFPE) tumor samples
were reviewed by a pathologist and the tumor area was se-
lected for analysis. A serial unstained tissue section was
manually dissected and subjected to Tissue lysis buffer
(Qiagen, Hilden, Germany). Following Proteinase-K diges-
tion and a decrosslink-step, DNA was automatically iso-
lated using a QiaSymphony® device (Qiagen, Hilden,
Germany) and subsequently quantified by OD 260 nm.
Workflow
A simple workflow for mutational testing has been
employed in routine diagnostics, which is depicted in
Fig. 1.
KRAS LCD-Array kit
The KRAS LCD-Array kit for detection of KRASmutations
in codon 12 and 13 (Exon 2) is based on the amplification
of a short PCR fragment and the subsequent identification
of point mutations by amplicon hybridization to immobi-
lized capture probes. Biotin labelling of the generated
170 bp PCR fragment occurs during PCR amplification.
Following a short hybridization to wild type and mutation
specific capture probes immobilized on the surface of the
LCD-Array, bound PCR fragments are visualized using the
sensitive streptavidin-enzyme-substrate cascade (Fig. 2).
To detect even small amounts of mutated KRAS se-
quences within an excess amount of wild type background,
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Fig. 1 The study workflow. All cases were tested by the KRAS LCD-array Kit and MALDI MS. If a mutation was found by the KRAS LCD-array Kit, a
report was signed out. If no mutation was detected by the KRAS LCD-array Kit, that covers exclusively exon 2, Sanger sequencing has been performed
for KRAS, NRAS and BRAF in exon 2–4 and a report was signed out accordingly
Fig. 2 Examples of KRAS mutations. a A representative example of a chromatogram. A KRAS mutation (c.183A > C; p.Q61H) in exon 3 as detected
by Sanger sequencing is depicted (arrow). Each mutation was observed on the forward and the reverse strand. b An example of a chip-hybridization
result from one patient. On top 3 type-specific double signals (arrowhead). On the left, the mutation-specific double signal (c35G> T; p.G12V) (arrow)
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amplification is carried out in the presence of the KRAS
Wildtype Supressor Compound (K-RAS WSC). This mol-
ecule preferentially suppresses wild type-sequence amplifi-
cation and therefore allows sequence-specific detection of
smallest amounts of KRAS mutations in codon 12 and 13.
Sanger sequencing
PCR primers were bought from Metabion (Munich,
Germany). PCR amplification products were purified by
ethanol precipitation and were bidirectionally sequenced
using Big Dye® v3.1 reagents (Thermo Fisher Scientific,
Waltham, USA) according to the manufacturer’s proto-
col. Sequencing products were purified using XTermina-
torTM beads (Thermo Fisher Scientific, Waltham, USA)
and automated sequencing performed by capillary elec-
trophoresis on an ABI3500 (Applied Biosystems). Se-
quences were aligned and examined by visual inspection
of the electropherogram (Fig. 2).
MALDI MS assay design
Relevant mutations of KRAS, NRAS and BRAF have been
identified from the COSMIC database and the respective
literature. DNA sequences were extracted from the UCSC
Genome Browser. These sequences were subsequently
utilized to build our multiplex assay with Assay Design
(v.3.0.0) covering KRAS mutations as rare as 0.002 %
according to the COSMIC database (Table 1).
MALDI MS mutation detection
After semi-automated DNA-Isolation (QIAsymphony®,
Qiagen, Hilden, Germany), DNA content was calculated
by NanoDropTM spectrophotometry (Peqlab, Erlangen,
Germany). PCR and downstream reactions were per-
formed according to the iPLEX Pro Kit® (Agena Bio-
science, Hamburg, Germany) datasheet. In brief, a
multiplex PCR-reaction (primers by Metabion, Munich,
Germany) was performed at a final volume of 5 μl con-
taining 10–100 ng template DNA leading to amplicon
sizes ranging from 88 to 127 bp.
To dephosphorylate unincorporated dNTPs, 2 μL of a
Shrimp-Alkaline-Phosphatase (SAP) Mix (iPlex® Pro Kit)
was added to each PCR reaction. After incubation steps
according to the manufacturer’s protocol, an extension pri-
mer reaction was performed to hybridize and elongate the
extension primers at the nucleotide position of interest.
Finally, the sample volume was increased by addition
of 42 μl ultrapure water and free ions were removed by
a resin cleanup step. 10–20 nl of the reaction products
were dispensed onto a matrix-precoated 96- well Spec-
troCHIP® bioarray by application of a nanodispenser
(RS1000, Agena Bioscience). MS experiments were con-
ducted on a MassArray® Analyser 4 system according to
the manufacturer’s protocol (Agena Bioscience, San
Diego). This system is specifically designed for the detec-
tion of genetic mutations and not for the detection of
other molecules. Results were analysed by MassArray®
Workstation software (v.3.3) (Agena Bioscience) (Fig. 3).
The general principle is based on amplification of the
DNA by PCR, resulting in copies of both mutant and
wildtype alleles. Primer extension performed using termin-
ator nucleotides A, C, T, G, each with distinct masses leads
to different masses of the amplicons depending on the
mutational status that can subsequently be detected by
mass spectrometry. If there is a mutant allele, three mass
peaks may be seen: the unextended primer peak, the amp-
lified wild-type allele peak and the amplified mutant allele
peak (Fig. 3). The ratio of the areas under the curve of
the wild-type allele and the mutant allele peaks are a
quantitative measure of the percentage of mutant alleles.
Next-generation sequencing (IonTorrent™)
For library preparation, the multiplex PCR-based Ion
Torrent AmpliSeq™ technology (Thermo Fisher Scientific,
Waltham, USA) was used. Amplicon library preparation
was performed with the Ion AmpliSeq Library Kit v2.0
using 10 ng of DNA. Briefly, the DNA was mixed with the
primer pool, containing all primers for generating the 180
amplicons and the Ampliseq HiFi Master Mix and trans-
ferred to a PCR cycler (BioRad, Munich, Germany). After
the end of the PCR reaction, primer end sequences were
partially digested using FuPa reagent, followed by the
ligation of barcoded sequencing adapters (Ion Xpress Bar-
code Adapters 1–16, Thermo Fisher Scientific, Waltham,
USA). The final library was purified using AMPure® XP
magnetic beads (Beckman Coulter, Krefeld, Germany) and
quantified using qPCR (Ion Library Quantitation Kit,
Thermo Fisher Scientific, Waltham, USA) on a StepOne®
qPCR machine (Thermo Fisher Scientific, Waltham,
USA). The individual libraries were diluted to a final con-
centration of 100pM and eight to ten libraries were pooled
and processed to library amplification on Ion Spheres
using Ion PGM™ template OT2 200Kit. Unenriched librar-
ies were quality-controlled using Ion Sphere quality con-
trol measurement on a QuBit® instrument. After library
enrichment (Ion OneTouch® ES), the library was processed
for sequencing using the Ion Torrent 200 bp sequencing
v2 chemistry and loaded onto a chip. Data analyses were
performed using the Ion Torrent Suite Software (v.4.2) as
described previously. We use a custom designed colon
cancer panel that includes KRAS and NRAS mutations in
exon 2, 3 and 4.
Table 1 Mutations covered in the MALDI MS array
KRAS: G12C, G12D, G12V, G12A, G12S, G12R, G13D,G13V, G13A, G13S,
Q61H, Q61E, Q61K, Q61R, Q61P, Q61L, K117N, A146T
NRAS: G12C, G12D, G12V, G12A, G12S, G12R, G13D,G13V, G13A, Q61H,
Q61E, Q61K, K117N, A146T
BRAF: V600E, V600K,V600R, V600L
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Results
KRAS and NRAS
A total of 93 samples from patients with CRC were ana-
lysed by MALDI MS and the KRAS LCD-array Kit. Since
the latter kit only detects KRAS mutations in exon 2, all
cases with KRAS wild-type status were further analysed by
Sanger sequencing of exons 3 and 4 of KRAS and exons
2,3 and 4 of NRAS (Fig. 1).
MALDI MS detected a KRAS mutation in 46/93
(49 %) tissue probes, from which 38/93 (41 %) were in
exon 2, 3/93 (3 %) were in exon 3 and 5/93 (5 %) were
in exon 4.
37/93 (40 %) of the KRAS mutations were already con-
firmed by the KRAS LCD-array kit, while additional 9/
93 (10 %) of KRAS mutations were confirmed by subse-
quent Sanger sequencing.
A mutation in the NRAS gene was identified in 2/93
(2 %) of cases. MALDI MS and Sanger sequencing were
in agreement in 2/2 (100 %) cases.
In total, MALDI MS results were in agreement to re-
sults obtained by the combination of the other two
methods in 92/93 (99 %) cases.
RAS-wild type tumors
Wild type tumors were analysed by three methods. Sanger
sequencing identified 44/93 (47 %), the KRAS LCD-array
kit 56/93 (60 %) and MALDI MS 44/93 (47 %) of patients
with wild type tumors.
One disconcordant case
In 1/93 (1 %) case a G12V mutation has been shown by
MALDI MS and Sanger sequencing, but not by the
Fig. 3 Representative examples of MALDI MS results. On the left, 16 cases plus wild type controle and no-template control tested for a KRAS
mutation (p.Q61H). 15 cases are KRAS wild-type (including the wild-type control); one of the cases is highlighted with an arrow (a). In this specific
case the sequencing primer (first arrow) is completely elongated by an Adenin indicated by a high peak in the mass range of the wild-type allele
(second arrow) (b). One case shows a mutation in KRAS (c.183A > C, p.Q61H) (c). The reverse sequence-specific primer is completely consumed
and elongated by either Thymine or Guanine (wild-type and mutated allele; arrows) (d)
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KRAS LCD-array kit. In this single case, NGS had been
performed and confirmed the presence of a G12V mu-
tation with an allele frequency of 15 %. Thus, MALDI
MS results were in agreement to results obtained by
the combination of three methods in 93/93 (100 %) of
the cases.
BRAF
BRAF was mutated in 1/93 (1 %) case respectively.
Again, MALDI MS and Sanger sequencing results were
in perfect agreement (100 %).
All mutations found occurred exclusively. The results
are summarized (Table 2).
Hands-on time and turnaround time
Overall hands-on time was shortest for the KRAS LCD-
array Kit and MALDI MS (45 min), intermediate for NGS
(70 min) and longest for Sanger sequencing (120 min).
The overall time-to-results was shortest for the KRAS
LCD-array Kit (220 min), followed by MALDI MS
(430 min), Sanger sequencing (715 min) and NGS
(1020 min).
Approximated times to perform each step of the differ-
ent methods namely KRAS LCD-array Kit, Sanger sequen-
cing, MALDI MS and NGS are summarized (Table 3).
Discussion
According to recent clinical guidelines it is mandatory to
evaluate the mutational status of oncogenes that act
downstream of EGFR specifically KRAS and NRAS in
mCRC in order to select a patient population that is most
likely to benefit from anti-EGFR therapy [5, 8, 14, 25].
Additionally, genes such as BRAF that provide prognostic
information may be included in the testing. Besides clas-
sical Sanger sequencing, new emerging techniques for the
detection of genetic mutations are available. Among them
Table 2 Detected mutations
KRAS-LCD
Array Kit
Sanger
Sequencing
MALDI
MS
NGS
KRAS
Mutation 37 9 46 1
A146T 0 4 4 0
A146V 0 1 1 0
G12A 2 0 2 0
G12C 1 0 1 0
G12D 16 0 16 0
G12R 1 0 1 0
G12S 1 0 1 0
G12V 11 1 12 1
G13D 5 0 5 0
Q61H 0 3 3 0
Wild type 56 44 44 0
NRAS
Mutation 2 0 2 0
G12D 1 0 1 0
G12V 1 0 1 0
Wild type 91 53 91 1
BRAF
Mutation 0 1 1 0
V600E 0 1 1 0
Wild type 93 52 92 1
Tested
Samples
93 53 93 1
Table 3 Estimated Hands-on-time and Time-to-results
KRAS LCD-array Kit Hands-on-time
in minutes
Time-to-result
in minutes
PCR reaction 15 150
Hybridization 20 60
Evaluation on PC 10 10
Overall 45 220
Sanger sequencing
PCR reaction 15 150
Gel preparation and electrophoresis 25 45
Ducumentation and Evaluation of
Dilution
10 10
Ethanolprecipitation and
centrifugation
20 35
Elution of the Pellets in pure water 10 10
Sequencing reaction 10 160
Add purification beads and
Incubation
10 40
Sequencing run for all exons (forward
and reverse)
10 250
Evaluation on PC 10 15
Overall 120 715
MALDI MS
PCR reaction 15 150
Dephosphorylation SAP reaction 5 60
Cycled MassEXTEND reaction 10 150
Sample conditioning, Nanodispensing 10 40
MS analysis and calling 5 30
Overall 45 430
NGS
Library Preparation 30 300
Emulsion PCR 10 360
Sequencing 20 300
Data analysis 10 60
Overall 70 1020
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MALDI MS has prompted particular interest among sci-
entists and pathologists, since it combines high sensitivity
and specificity with low cost per test, fast turnaround time
and easy sample handling [17].
Sensitivity and specificity
Sanger sequencing is generally considered to be the
gold standard for the detection of mutations in KRAS,
NRAS and BRAF. Specificity is generally high with all
methods applied for the detection of genetic mutations
[30, 32, 34–36]. However, sensitivity has been reported
to differ [34, 37].
Whereas direct sequencing has been reproducibly shown
to have a detection limit of >10 % mutant alleles, high reso-
lution melting analysis has a lower detection limit of 10 %
[38] that is similar to SnP shot assays (10 %) [27] and can
further be improved by the cobasR test (5 %) [39], the Ther-
aScreen® test (1 %) [33, 38, 40–42] or Strip assays (1 %)
[27, 38]. Also, NGS [34] and MALDI MS have similarly
low detection limits of 1–5 % mutant allels [28, 33, 34,
38–44]. Altimari et al. [34] state that NGS was superior in
terms of sensitivity and specificity compared to other tech-
niques in detecting KRAS mutations in FFPE material, but
MALDI MS was not included in their analysis.
To improve both, sensitivity and specificity, in direct
sequencing, especially in specimen with low amount of
DNA, it was recommended to increase the number of
PCR cycles. Also to avoid false –positive errors, duplica-
tion of the test was expected to be effective [33]. Amplifi-
able DNA amounts are often limited when FFPE samples
are used as a source, since DNA is highly fragmented by
formalin treatment [33].
It has also been shown that various methods tested in
different laboratories showed a decreasing correct muta-
tional allele frequency proportionally with decreasing
percentage of tumor cell content [26].
Therefore macro- or micro-dissection of the tumor
area is usually done, which improves the test results and
is therefore strongly recommended [45]. Tumor cell en-
richment correlated significantly with the abundance of
KRAS-mutated DNA [34].
Discordant results of different methods were attributed
to tumor heterogeneity, contamination of the tumor sam-
ple with normal tissue, analytic factors affecting assay sen-
sitivity and lack of experience with the respective method
[19, 34, 35].
However, despite efforts to improve Sanger sequencing
it has been shown that the sensitivity the specificity of
mass spectrometrical methods exceeds that of traditional
Sanger sequencing and is highly concordant with pyrose-
quencing, allelee-specific PCR [17, 46–48] and NGS
[49]. In our study DNA quality was sufficient in all cases
and none of the MALDI MS, NGS or Sanger sequencing
reactions had to be repeated.
Cost
When estimating the cost of a test, three parameters
have to be considered, cost of instrumentation, consum-
able cost per test and hands-on-time. In the literature
relatively few statements about costs of the different
methods could be obtained.
Sarasqueta et al. reported low costs per test for direct
sequencing and SNap shot® compared to a Strip assay
[27]. But the advantage of strip or chip hybridisation
after PCR is low cost for technical equipment [45].
High performance of the PNA clamp PCR assay and
low cost compared to TheraScreen® test assay was re-
ported by Norgard et al. [43]. The reagent costs for py-
rosequencing and Sanger sequencing were comparable
but higher than that of melting curve analysis in one
study [30].
Likewise, costs per sample in Sanger sequencing is
higher compared to MALDI MS, especially when com-
plex testing of numerous mutations was performed [17].
In a previous study, we reported equipment cost to be
highest with Sanger and pyrosequencing, followed by
real-time- and array-based systems. Costs per sample
were lowest for Sanger and pyrosequencing, two-fold
higher for the array and three-fold higher for high reso-
lution melting curve analysis [45].
NGS and MALDI MS have comparable costs for the
technical equipment, but costs per test are much lower
in MALDI MS especially when a customized assay for
mutation detection is build. It is important to mention,
that local prices for equipment and tests may vary
considerably.
Hands-on-time is an important cost factor and has
been reported to be around 2 h for Sanger sequencing,
SNap shot® assays, Therascreen, high resolution melting
curve analysis, NGS and MALDI MS [27, 38, 50]. The
StripAssays may be conducted within 1,5 h [27]. Melting
curve analysis has the shortest hands on time compared
to the other mentioned methods [30, 45]. In our study
hands-on time was around 45 min for performing the
KRAS LCD-Kit and MALDI MS, 70 min for NGS and
around 2 h for Sanger sequencing.
In the authors opinion MALDI MS is the most cost
effective method to detect clinically relevant mutations
in CRC. Since it is an open platform more mutational
hotspots for testing may be easily added. However, this
holds only true for high throughput laboratories, since
the equipment costs are rather high compared to array-
or real-time PCR based methods or high resolution
melting curve analysis. For laboratories with low
throughput, techniques with low equipment costs and
high costs per sample may be more cost effective on
the short and also on the long term. Therefore definite
conclusions regarding cost-effectiveness cannot easily
be generalized.
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Turnaround time
Besides hands-on-time turnaround time/time-to-result is
important and has been reported to be 2 working days
for Sanger sequencing, 1.5 working days for SNaP shot
and pyrosequencing and 1 working day for Strip- and chip
assays [27, 38, 45, 51] which is in line with our results.
With respect to turnaround time high resolution melting
curve analysis has been reported to outperform the former
mentioned methods [45]. We perform MALDI MS muta-
tional testing within 1.5 working days. In our opinion a
time-to-result of around 2 working days seems reasonable,
but if the time line is critical one might choose high reso-
lution melting curve analysis as the preferred method.
However, as previously mentioned this method harbours
some disadvantages as false-positive results may occur
more frequently and costs per test are high compared to
the other methods [38, 45].
KRAS and NRAS
We detected KRAS mutations by MALDI MS in 49 % of
all samples analysed which is in perfect accordance with
other reports [17, 41, 45]. In one case MALDI MS and
Sanger sequencing detected a mutation but the KRAS
LCD-array kit failed to do so. At first, it was unclear
whether the detection of the G12V mutation could be
attributed to lower detection limits of MALDI MS com-
pared to the chip-assay or if this case represented a
false-positive result. Since it has been proven in the past
that MALDI MS and NGS yield similar results [49], a
NGS experiment has been performed. Indeed, the very
same mutation could be confirmed at an allelic fre-
quency of approximately 15 % by NGS. Taken all three
alternative methods together, MALDI MS showed con-
cordant results in 100 % of the cases. This proves the
perfect reliability of MALDI MS mutational testing. It is
recommended by several authors to test for all codons
of KRAS. We included mutations in our panel that oc-
curred in frequencies as low as 0.002 % of cases in CRC
according to the COSMIC database because in our opin-
ion this represents a reasonable trade-off between sensitiv-
ity and wise handling of resources. NRAS mutations were
detected in 3 % of our cases, again well in accordance with
other reports [8, 10, 11]. Concordance of NRAS testing
was 100 % between the three methods applied. As all
KRAS and NRAS mutations have been shown to have
lower response rates to anti-EGFR therapy compared to
RAS wild-types [10], mutational testing for both should be
standard of care for all mCRC.
BRAF
Besides mutations of KRAS and NRAS, the BRAF gene
plays a critical role in CRC. It has been shown that
BRAF mutations are frequent in sporadic CRC with MSI
(32–74 %) and in serrated polyps (up to 90 % in sessile
serrated adenomas [52]). The improved classification of
serrated lesions by BRAF mutation testing may bet the
key to identify lesions with a higher potential to progres-
sion into BRAF V600E mutated CRC [53].
This subset of tumors is characterized by right-sided
location in the colon, prevalence of mucin, high levels of
promoter methylation of CpG islands (CIMP) and a
good prognosis compared to its BRAF wild type coun-
terparts with 5-year survival rates over 70 % [17, 54, 55].
In contrast a small subset of BRAF mutated CRC
harbour MSS (4 %) and have a significantly worse prog-
nosis with 5-year survival rates of only 16,7 % [21]. Test-
ing for a BRAF mutation alone is therefore not sufficient
but adds significant prognostic information in combin-
ation with MSI/MSS testing. Of note is that hereditary
non-poliposis colorectal carcinomas (HNPCC) generally
do not exhibit BRAF mutations, therefore it might be
tested to exclude such a hereditary form of CRC.
Thus we added testing for BRAF mutations to our cus-
tomized panel in order to be able to provide improved
prognostic information in conjunction with microsatel-
lite testing.
In our cohort one case with BRAF mutation has been
found by MALDI-MS and Sanger Sequencing. Our inci-
dence of only 1 % BRAF mutations is probably due to
the rather low sample size considering that BRAF muta-
tions have been reported in the literature at a frequency
of 5–20 % of all CRC.
MALDI MS
The MALDI MS technology has the advantage that tests
with adequate quality standards may be designed and
that it is an open platform which allows fast inclusion of
complex mutations of various gens that may be import-
ant in the future. Although the clinical significance of
mutations with low allelic frequency in relation to prog-
nosis and therapeutic benefit has yet not fully under-
stood, MALDI MS is very specific, significantly more
sensitive than Sanger sequencing and reaches detection
limits comparable to other modern technologies such as
NGS. In addition, for laboratories with a high through-
put it combines the advantage of low hands-on time, fast
turnaround time and cost effectiveness.
Conclusion
Taken together evaluation of KRAS and NRAS muta-
tional status for therapeutic requirements and BRAF
mutational analysis by MALDI MS for prognostic and
classification purposes is clearly an attractive approach
for routine diagnostics.
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